Hormonal
Elevated plasma branched-chain amino acid (BCAA) levels contribute to the development of insulin resistance through multiple mechanisms, including mTOR/S6K-mediated inhibition of insulin signaling, inhibition of pyruvate dehydrogenase (PDH), and accumulation of toxic metabolites causing mitochondrial dysfunction.
If you have insulin resistance or Type 2 Diabetes, be mindful of very high intakes of branched-chain amino acids (found in red meat, dairy, and supplements), especially when combined with high-fat meals, as this may worsen insulin sensitivity. Focus on balanced protein intake rather than extreme high-protein or high-fat combinations, and prioritize exercise which helps clear BCAA.
Evidence indicates that plasma BCAAs act as signaling molecules and contribute to the development of insulin resistance in humans... Several mechanisms have been hypothesized explaining how plasma BCAA levels contribute to insulin resistance... Elevated BCAA levels could lead to persistent activation of mTOR followed by serine phosphorylation of IRS-1 via S6 kinase (p70S6K)... accumulation of BCAA and its derived metabolites can also directly inhibit PDH activity... dysfunctional mitochondrial BCAA catabolism may cause anaplerotic stress thereby dysregulating glucose and fat oxidation.
Why this rating
The paper is a review citing multiple human observational studies, rodent models, and in vitro data, but notes that direct causal evidence in humans is still limited.
Source
Role of branched-chain amino acid metabolism in the pathogenesis of obesity and type 2 diabetes-related metabolic disturbances BCAA metabolism in type 2 diabetes
Froukje Vanweert et al. · Nutrition and Diabetes · 2022
DOI 10.1038/s41387-022-00213-3
More from this paper
- Endurance and resistance exercise training lowers plasma BCAA levels and enhances BCAA oxidation, serving as a natural strategy to mitigate BCAA-related insulin resistance.Good
- Pharmacological activation of the BCKD complex using agents like BT2 or Sodium Phenylbutyrate (NaPB) accelerates BCAA catabolism, lowers plasma BCAA levels, and improves insulin sensitivity in animal models of obesity and diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →